ESMO 2021 - Results from #20

Viewing 21-40 of 137 articles

ESMO 2021: Future Targets and Combinations for Metastatic Renal Cell Carcinoma

ESMO 2021: Current Status of Personalized Therapy in Metastatic Renal Cell Carcinoma

ESMO 2021: Invited Discussant: Decreasing Morbidity for the Treatment of Stage II Seminoma

ESMO 2021: Is There an Optimal First-Line Combination Approach for Metastatic mRCC?

ESMO 2021: Invited Discussant: Modified Delivery of RCC Therapy: Can we Maintain Efficacy and Improve Quality of Life?

ESMO 2021: CheckMate 9KD Cohort A2 Final Analysis: Nivolumab + Rucaparib for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

ESMO 2021: Phase Ib/II Study of Sabizabulin (VERU-111), an Androgen Receptor Transport Disruptor, in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Failed an Androgen Receptor Targeting Agent

ESMO 2021: Darolutamide Maintenance in Metastatic Castration Resistant Prostate Cancer Previously Treated with Novel Hormonal Agents and Non-Progressive Disease After Subsequent Treatment with a Taxane: SAKK 08/16

ESMO 2021: Health-Related Quality of Life (HRQoL), Pain and Safety Outcomes in the Phase III VISION Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer

ESMO 2021: Enhanced Androgen Signaling Inhibition: A Requirement in the Upfront Treatment of Advanced Hormone-Sensitive Prostate Cancer

ESMO 2021: CheckMate 9KD Cohort A2 Final Analysis: Nivolumab + Rucaparib for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ESMO 2021: Phase 1b/2 Study of Sabizabulin (VERU-111), an Androgen Receptor Transport Disruptor, in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Failed an Androgen Receptor Targeting Agent

ESMO 2021: A Discussion on the Role of Abiraterone in Combination with Docetaxel and the Role of Abiraterone in Combination with ADT

ESMO 2021: A Phase 3 Trial with a 2x2 Factorial Design in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival with Abiraterone Acetate plus Prednisone in PEACE-1

ESMO 2021: Health-Related Quality of Life, Pain and Safety Outcomes in the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients with mCRPC

ESMO 2021: Abiraterone Acetate plus Prednisolone with or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone for Men with High-Risk Non-Metastatic Prostate Cancer

ESMO 2021: Darolutamide Maintenance in mCRPC Previously Treated with Novel Hormonal Agents and Non-Progressive Disease After Subsequent Treatment with a Taxane: A Randomized Double-Blind Placebo-Controlled Phase II Trial (SAKK 08/16)

ESMO 2021: STAR: A Randomized Multi-Stage Phase II/III Trial of Standard First-Line Therapy (Sunitinib or Pazopanib) Comparing Temporary Cessation with Allowing Continuation, in the Treatment of Locally Advanced And/or Metastatic RCC

ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival With Abiraterone Acetate Plus Prednisone in PEACE-1

ESMO 2021: Pembrolizumab Versus Placebo as Adjuvant Therapy for Patients with RCC: Patient-Reported Outcomes in KEYNOTE-564

1
2
3
4
5
6
7